MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
Top Page
MoonLake Immunotherapeutics
(NASDAQ:MLTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$20.00
▲(3.04% Upside)
Action:ReiteratedDate:04/02/26
The score is primarily constrained by weak financial performance (no revenue, accelerating losses and cash burn, and rising debt), partly offset by positive corporate catalysts (favorable FDA feedback and strong Phase 2 data) and a mixed-to-slightly constructive momentum picture. Valuation inputs are not very informative due to negative earnings and no dividend.
Positive Factors
Strong Phase 2 S-OLARIS efficacy
Robust Phase 2 efficacy (81% ASAS40) with supportive imaging and biomarker signals strengthens the clinical profile of sonelokimab. Durable high efficacy and mechanistic biomarker support increase probability of successful late-stage outcomes, partner interest, and regulatory confidence over upcoming 2–6 months.
Negative Factors
Pre-revenue with accelerating losses and cash burn
The company remains pre-revenue with rapidly widening losses and worsening operating cash flow, reflecting an intensifying burn phase. Structurally this raises financing dependency and execution risk over the medium term, forcing reliance on external capital if clinical timelines slip or costs rise further.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Phase 2 S-OLARIS efficacy
Robust Phase 2 efficacy (81% ASAS40) with supportive imaging and biomarker signals strengthens the clinical profile of sonelokimab. Durable high efficacy and mechanistic biomarker support increase probability of successful late-stage outcomes, partner interest, and regulatory confidence over upcoming 2–6 months.
Read all positive factors
MoonLake Immunotherapeutics (MLTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.39B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth-157.74%
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.93
Shares Outstanding71,727,875
10 Day Avg. Volume1,512,708
30 Day Avg. Volume1,055,284
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-506.45
Enterprise Value/Ebitda-5.16
Forecast
1Y Price Target
$28.57Price Target Upside47.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.62
Revenue Forecast (FY)N/A
MoonLake Immunotherapeutics Business Overview & Revenue Model
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducti...
How the Company Makes Money
As a clinical-stage biotechnology company, MoonLake Immunotherapeutics does not have recurring revenue from marketed products; its primary activities are research and development and advancing clinical programs. Detailed, company-specific breakdow...
MoonLake Immunotherapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.62M | 0.00 | 0.00 | 0.00 | -4.97K |
| EBITDA | -219.85M | -141.71M | -53.75M | -64.90M | -53.63M |
| Net Income | -227.32M | -118.94M | -36.01M | -49.97M | -53.64M |
Balance Sheet | |||||
| Total Assets | 424.43M | 477.93M | 526.54M | 76.84M | 9.68M |
| Cash, Cash Equivalents and Short-Term Investments | 393.97M | 448.03M | 511.01M | 72.11M | 8.04M |
| Total Debt | 75.71M | 2.83M | 3.70M | 282.58K | 15.00M |
| Total Liabilities | 119.95M | 24.54M | 13.05M | 8.08M | 21.33M |
| Stockholders Equity | 304.48M | 446.83M | 495.68M | 48.90M | -11.65M |
Cash Flow | |||||
| Free Cash Flow | -196.04M | -117.11M | -43.06M | -55.91M | -35.23M |
| Operating Cash Flow | -196.01M | -116.59M | -42.78M | -55.89M | -35.18M |
| Investing Cash Flow | 202.99M | -205.60M | -25.18M | -32.34M | -50.71K |
| Financing Cash Flow | 146.00M | 51.31M | 479.70M | 119.69M | 43.26M |
MoonLake Immunotherapeutics Technical Analysis
Positive
19.41
Price Trends
17.11
Positive
15.69
Positive
27.21
Negative
Market Momentum
0.28
Negative
61.50
Neutral
75.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLTX, the sentiment is Positive. The current price of 19.41 is above the 20-day moving average (MA) of 17.25, above the 50-day MA of 17.11, and below the 200-day MA of 27.21, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 61.50 is Neutral, neither overbought nor oversold. The STOCH value of 75.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLTX.
MoonLake Immunotherapeutics Risk Analysis
MoonLake Immunotherapeutics disclosed 65 risk factors in its most recent earnings report. MoonLake Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MoonLake Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.64B | -42.66 | -19.89% | ― | -35.39% | -72.97% | |
56 Neutral | $5.20B | 141.40 | 8.20% | ― | 42.11% | ― | |
55 Neutral | $4.15B | -8.91 | -41.46% | ― | ― | -21.96% | |
54 Neutral | $1.39B | -3.74 | -67.12% | ― | ― | -157.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.37B | -11.01 | -22.81% | ― | 23.73% | 30.16% |
* Healthcare Sector Average
MLTX
MoonLake Immunotherapeutics
19.41
-15.49
-44.38%
PTGX
Protagonist Therapeutics
104.09
61.46
144.22%
ZLAB
Zai Lab
20.74
-8.80
-29.79%
APLS
Apellis Pharmaceuticals
40.65
21.23
109.32%
CRNX
Crinetics Pharmaceuticals
39.63
10.52
36.14%
MoonLake Immunotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
MoonLake Highlights Positive S-OLARIS Data and Investor Day
Positive
Feb 23, 2026
On February 20, 2026, MoonLake Immunotherapeutics amended its loan and security agreement with Hercules Capital, expanding a senior secured credit facility to six tranches totaling up to $500 million and drawing an additional $25 million. The amen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.